Highest-materiality recent filing
Tevogen Bio receives Nasdaq deficiency notices for market value requirements
Nasdaq notified Tevogen on Apr 16, 2026 it fails $50M minimum market value for listed securities (MVLS).
Reverse stock split ratio 1-for-50; effective 12:01 a.m. March 6, 2026.
Tevogen Bio shareholders approve 100M share increase and reverse stock split authorization
Shareholders approved amending 2024 Omnibus Incentive Plan to add 100,000,000 shares, effective Feb 19, 2026.
Tevogen Bio gets Nasdaq deficiency notice; must regain $1.00 bid by March 2026
Received letter on September 23, 2025 from Nasdaq Staff for non-compliance with $1.00 minimum bid price rule.
Tevogen Bio enters $50M at-the-market equity sales agreement with A.G.P.
Sales agreement allows issuance and sale of up to $50M of common stock from time to time.
Tevogen Bio receives $2M grant from KRHP LLC; up to $10M non-dilutive funding
Initial $2M grant from KRHP LLC; additional $8M contingent on KRHP's review of activities.
Tevogen Bio raises $6M via Series C Preferred Stock; two closings Aug 30 & Sept 16
Investor to purchase 600 shares of Series C Preferred Stock for $6.0 million aggregate.
Tevogen Bio raises $6M via Series C Preferred; director Suren Ajjarapu resigns
Sold 600 shares of Series C Preferred at $10,000 each for $6.0M aggregate to The Patel Family, LLP.
Tevogen Bio receives Nasdaq bid price deficiency notice, repurchases Series B Preferred Stock
Received Nasdaq letter on June 14, 2024, for non-compliance with $1.00 minimum bid price rule for 35 consecutive business days.
Tevogen Bio secures $36M unsecured credit line from 5% owner Patel Family; equity-linked terms
Loan agreement with The Patel Family LLP (affiliate of 5% holder Manmohan Patel) for up to $36M unsecured facility.
Tevogen Bio Inc reports 2023 net loss of $60.5M; cash only $1.05M, going concern raised
Net loss of $60.5M in 2023 ($2.44/share) vs $22.0M in 2022; no revenue.
Tevogen Bio enters $36M line of credit with Patel Family; also grants PIPE option for $14M+
Line of credit up to $36M, draws limited to $1M per month; interest lower of SOFR+2% or 7%.
Tevogen Bio Holdings appoints KPMG as auditor, dismisses Marcum
Audit committee appointed KPMG as independent auditor for FY2024, effective immediately.
Tevogen Bio's audited FY2023 shows $60.5M net loss, going concern doubt
Net loss of $60.5M in 2023 vs $22.0M in 2022; accumulated deficit $99.7M.
Expects to report $94.9M liability elimination from conversion of promissory notes into common stock.
On August 20, 2024, Suren Ajjarapu gave notice of his resignation from service as a director of the Company, effective August 21, 2024.
Max materiality 0.85 · Median 0.60 · Most common event other_material